GlassScriptPhysician profile
Amelework A Kebede
NPI 1063707883
$1,423.99
in general payments reported to CMS, 2019-2025
15 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $63.46 · 2021: $231 · 2022: $124 · 2023: $323 · 2024: $377 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $449.77 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $217.64 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $173.91 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $124.37 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Ucb, INC. | $90.74 | 2019-2024 | Briviact |
| Novartis Pharmaceuticals Corporation | $62.16 | 2019-2024 | |
| Smith+Nephew, INC. | $60.49 | 2021-2025 | Collagenase Santyl |
| E.R. Squibb & Sons, L.L.C. | $54.41 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $48.37 | 2020-2023 | Lokelma |
| Mylan Specialty L.P. | $44.47 | 2021-2022 | |
| Fisher & Paykel Healthcare INC | $25.45 | 2024 | Fisher & Paykel Healthcare |
| Gilead Sciences, INC. | $21.53 | 2022 | |
| Livanova USA, INC. | $20.37 | 2020 | |
| Vapotherm INC | $17.29 | 2024 | Vapotherm |
| Sanofi-Aventis U.S. LLC | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelework Kebede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.